Roivant Sciences Ltd.
GBFinancials
Valuation Metrics
Roivant Sciences Ltd.'s Market Cap is $28.76B. At end of 2025 it was $15.12B. Ranked #467 of 3,121 in US market (top 15%), #140 of 1,463 on NASDAQ (top 10%), #26 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $28.76B | US#467/3,121 Sec#26/266 |
| Revenue | $8M | US#2,841/3,121 Sec#173/266 |
| Net Income | $-266M | US—/3,121 Sec—/266 |
| Total Assets | $5.31B | US#1,412/3,121 Sec#38/266 |
| Net Assets | $4.23B | US#788/3,121 Sec#31/266 |
| Employees | 750 | US#2,108/3,121 Sec#67/266 |
| Value | ||
| P/B | 6.80x | US#2,434/3,121 Sec#169/266 |
| P/S | 3481.41x | US#2,996/3,121 Sec#203/266 |
| FCF Yield | -2.83% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -6.29% | US#2,296/3,121 Sec#75/266 |
| ROA | -5.02% | US#2,517/3,121 Sec#87/266 |
| Op. Margin | -18140.92% | US#2,879/3,121 Sec#191/266 |
| Revenue Growth | -67.58% | US#2,756/3,121 Sec#172/266 |
| Financial Health | ||
| Debt Ratio | 9.09% | US#93/3,121 Sec#43/266 |
| Total Debt | $107M | US#2,428/3,121 Sec#118/266 |
| FCF | $-814M | US#2,947/3,121 Sec#259/266 |
| Cash | $1.25B | US#589/3,121 Sec#27/266 |
| Current Ratio | 16.72x | US#147/3,121 Sec#39/266 |
| Performance | ||
| 1Y Return | 161.65% | US#96/3,121 Sec#40/266 |
| 1M Return | 6.98% | US#358/3,121 Sec#40/266 |
| From 52W High | -5.93% | US#383/3,121 Sec#28/266 |
| 1Y MDD | -12.84% | US#175/3,121 Sec#6/266 |
| Trading | ||
| Volume | 7,417,419 shares | US#217/3,121 Sec#16/266 |
| Trading Value | $298M | US#314/3,121 Sec#15/266 |
| Per Share | ||
| EPS | $-0.37 | US—/3,121 Sec—/266 |
| BPS | $5.88 | US#2,206/3,121 Sec#114/266 |
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.